Author's Reply

1. Coyle JD , Gardner SF , White CM . The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus. Ann Pharmacother 2004; 38: 1731–8. DOI 10.1345/aph.1E182

2. Pitt B , Segal R , Martinez FA , Meurers G , Cowley AJ , Thomas I , Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–52.

3. Pitt B , Poole-Wilson PA , Segal R , Martinez FA , Dickstein K , Camm AJ , Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial—the Losartan Heart Failure Survival Study, ELITE II. Lancet 2000; 355: 1582–7.

4. Cohn JN , Tognoni G . A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–75.

5. Maggioni AP , Anand I , Gottlieb SO , Latini R , Tognoni G , Cohn JN . Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002; 40: 1414–21.

6. Pfeffer MA , Swedberg K , Granger CB , Held P , McMurray JJ , Michelson EL , Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. 2003; 362: 759–66.

7. McMurray JJ , Ostergren J , Swedberg K , Granger CB , Held P , Michelson EL , Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767–71.

8. Granger CB , McMurray JJ , Yusuf S , Held P , Michelson EL , Olofsson B , Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–6.

9. Yusuf S , Pfeffer MA , Swedberg K , Granger CB , Held P , McMurray JJ , Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003; 362: 777–81.

10. Pfeffer MA , McMurray JJ , Velazquez EJ , Rouleau JL , Kober L , Maggioni AP , Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906.

11. Dahlof B , Devereux RB , Kjeldsen SE , Julius S , Beevers G , de Faire U , Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.

12. Papademetriou V , Varsang C , Elmfeldt D , Hofman A , Lithell H , Olofsson B , Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the study on cognition and prognosis in the elderly (SCOPE). J Am Coll Cardiol 2004; 44: 1175–80.

13. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (suppl 1): S1–290.

14. American Diabetes Association 2004 Clinical Practice Recommendations. Diabetes Care 2004; 27 (suppl 1): S1–150.

15. Vivian EM , Goebig ML . Slowing the progression of renal disease in diabetic patients. Ann Pharmacother 2001; 35: 452–63. DOI 10.1345/aph.10067